A new definition for metabolic dysfunction-associated fatty liver disease: An international expert consensus statement

Journal of Hepatology - Tập 73 Số 1 - Trang 202-209 - 2020
Mohammed Eslam1, Philip N. Newsome2,3,4, Shiv Kumar Sarin5, Quentin M. Anstee6,7, Giovanni Targher8, Manuel Romero‐Gómez9, Shira Zelber‐Sagi10,11, Grace Lai‐Hung Wong12, Jean‐François Dufour13,14, Jörn M. Schattenberg15, Takumi Kawaguchi16, Marco Arrese17, Luca Valenti18, Gamal Shiha19, Claudio Tiribelli20, Hannele Yki‐Järvinen21, Jian-Gao Fan22, Henning Grønbæk23, Yusuf Yılmaz24,25, Helena Cortez‐Pinto26, Cláudia P. Oliveira27, Pierre Bédossa28, Leon A. Adams29, Ming‐Hua Zheng30,31, Yasser Fouad32, Wah‐Kheong Chan33, Nahúm Méndez‐Sánchez34, Sang Hoon Ahn35, Laurent Castéra36, Elisabetta Bugianesi37, Vlad Ratziu38, Jacob George1
1Storr Liver Centre, Westmead Institute for Medical Research, Westmead Hospital and University of Sydney, NSW, Australia
2Centre for Liver and Gastrointestinal Research, Institute of Immunology and Immunotherapy, University of Birmingham, UK
3Liver Unit, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
4National Institute for Health Research Biomedical Research Centre at University Hospitals Birmingham NHS Foundation Trust and the University of Birmingham, UK
5Department of Hepatology, Institute of Liver and Biliary Sciences, New Delhi, India
6Newcastle NIHR Biomedical Research Centre, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom
7Translational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom
8Section of Endocrinology, Diabetes and Metabolism, Department of Medicine, University and Azienda Ospedaliera Universitaria Integrata of Verona, Verona, Italy
9UCM Digestive Diseases, Virgen del Rocio University Hospital, Instituto de Biomedicina de Sevilla, CIBEREHD, University of Seville, Sevilla, Spain
10Department of Gastroenterology, Tel Aviv Medical Center, Tel Aviv, Israel
11School of Public Health, University of Haifa, Haifa, Israel
12Department of Medicine and Therapeutics, The Chinese University of Hong Kong, Hong Kong
13Department of Biomedical Research, University of Bern, Switzerland
14University Clinic for Visceral Surgery and Medicine, Inselspital, University of Bern. Switzerland
15Department of Medicine, University Medical Centre, Johannes Gutenberg University Mainz, Germany
16Division of Gastroenterology, Department of Medicine, Kurume University School of Medicine, Kurume, Japan
17Departamento de Gastroenterología, Escuela de Medicina, Pontificia Universidad Católica de Chile, Santiago, Chile and Centro de Envejecimiento y Regeneracion (CARE), Departamento de Biologia Celular y Molecular, Facultad de Ciencias Biologicas Pontificia Universidad Catolica de Chile, Santiago, Chile
18Department of Pathophysiology and Transplantation, Università degli Studi di Milano, and Translational Medicine, Department of Transfusion Medicine and Hematology, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
19Hepatology and Gastroenterology Unit, Internal Medicine Department, Faculty of Medicine, Mansoura University, Egypt
20Liver Center, Italian Liver Foundation, Trieste, Italy
21Department of Medicine, University of Helsinki and Helsinki University Hospital, and Minerva Foundation Institute for Medical Research, Helsinki, Finland
22Center for Fatty Liver, Department of Gastroenterology, Xin Hua Hospital Affiliated To Shanghai Jiao Tong University School of Medicine, Shanghai Key Lab of Pediatric Gastroenterology and Nutrition, Shanghai, China
23Department of Hepatology & Gastroenterology, Aarhus University Hospital, Aarhus, Denmark
24Department of Gastroenterology, School of Medicine, Marmara University, Istanbul, Turkey
25Institute of Gastroenterology, Marmara University, Istanbul, Turkey
26Clínica Universitária de Gastrenterologia, Laboratório de Nutrição, Faculdade de Medicina, Universidade de Lisboa, Portugal
27Department of Gastroenterology, University of Sao Paulo School of Medicine, Sao Paulo, Brazil
28Department of Pathology, Physiology and Imaging, Beaujon Hospital Paris Diderot University, Paris, France
29Medical School, Sir Charles Gairdner Hospital Unit, University of Western Australia, Nedlands, WA, Australia
30Institute of Hepatology, Wenzhou Medical University, Wenzhou, China
31NAFLD Research Center, Department of Hepatology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China
32Department of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Minia University Hospitals, Minya, Egypt
33Gastroenterology and Hepatology Unit, Department of Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
34Liver Research Unit, Medica Sur Clinic & Foundation and Faculty of Medicine. National Autonomous University of Mexico, Mexico City, Mexico
35Department of Internal Medicine, Yonsei University College of Medicine, Seoul, South Korea
36Université Paris VII, Inserm Umr 1149, Centre de Recherche Sur L'inflammation, Paris, France
37Division of Gastroenterology and Hepatology, Department of Medical Sciences, University of Turin, Turin, Italy
38Sorbonne Université, Assistance Publique-Hôpitaux de Paris, Hôpital Pitié Salpêtrière-, Institute of Cardiometabolism and Nutrition (ICAN), Paris, France

Tóm tắt

Từ khóa


Tài liệu tham khảo

Eslam, 2020, MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease, Gastroenterology, 10.1053/j.gastro.2019.11.312

Younossi, 2018, Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention, Nat Rev Gastroenterol Hepatol, 15, 11, 10.1038/nrgastro.2017.109

Sarin, 2020, Liver diseases in the Asia-Pacific region: a Lancet Gastroenterology & hepatology Commission, Lancet Gastroenterol Hepatol, 5, 167, 10.1016/S2468-1253(19)30342-5

Inoue, 2018, Epidemiology of obesity in adults: latest trends, Curr Obes Rep, 7, 276, 10.1007/s13679-018-0317-8

Stefan, 2017, Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans, Cell Metab, 26, 292, 10.1016/j.cmet.2017.07.008

Araujo, 2019, Prevalence of optimal metabolic health in American adults: national health and nutrition examination survey 2009-2016, Metab Syndr Relat Disord, 17, 46, 10.1089/met.2018.0105

Eslam, 2019, Toward more accurate nomenclature for fatty liver diseases, Gastroenterology, 157, 590, 10.1053/j.gastro.2019.05.064

Byrne, 2015, NAFLD: a multisystem disease, J Hepatol, 62, S47, 10.1016/j.jhep.2014.12.012

Cleeman, 2001, Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III), JAMA, 285, 2486, 10.1001/jama.285.19.2486

Black, 2003, The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report, JAMA, 289, 2560, 10.1001/jama.289.19.2560

Grundy, 2005, Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement, Circulation, 112, 2735, 10.1161/CIRCULATIONAHA.105.169404

Alberti, 2009, Circulation, 120, 1640, 10.1161/CIRCULATIONAHA.109.192644

Whelton, 2018, J Am Coll Cardiol, 71, e127, 10.1016/j.jacc.2017.11.006

Association, 2018, 2. Classification and diagnosis of diabetes: standards of medical care in diabetes—2018, Diabetes Care, 41, S13, 10.2337/dc18-S002

Siddiqui, 2018, Case definitions for inclusion and analysis of endpoints in clinical trials for nonalcoholic steatohepatitis through the lens of regulatory science, Hepatology, 67, 2001, 10.1002/hep.29607

2016, EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease, J Hepatol, 64, 1388, 10.1016/j.jhep.2015.11.004

Wong, 2018, Asia-pacific working party on non-alcoholic fatty liver disease guidelines 2017-Part 1: definition, risk factors and assessment, J Gastroenterol Hepatol, 33, 70, 10.1111/jgh.13857

Chalasani, 2018, The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases, Hepatology, 67, 328, 10.1002/hep.29367

Eddowes, 2019, Accuracy of FibroScan controlled attenuation parameter and liver Stiffness Measurement in assessing steatosis and fibrosis in patients with nonalcoholic fatty liver disease, Gastroenterology, 156, 1717, 10.1053/j.gastro.2019.01.042

Caussy, 2018, Noninvasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials, Hepatology, 68, 763, 10.1002/hep.29797

Di Angelantonio, 2016, Body-mass index and all-cause mortality: individual-participant-data meta-analysis of 239 prospective studies in four continents, Lancet, 388, 776, 10.1016/S0140-6736(16)30175-1

Shea, 2011, The prevalence of metabolically healthy obese subjects defined by BMI and dual-energy X-Ray absorptiometry, Obesity, 19, 624, 10.1038/oby.2010.174

Munoz-Garach, 2016, Does metabolically healthy obesity exist?, Nutrients, 8, 10.3390/nu8060320

Eckel, 2018, Transition from metabolic healthy to unhealthy phenotypes and association with cardiovascular disease risk across BMI categories in 90 257 women (the Nurses' Health Study): 30 year follow-up from a prospective cohort study, Lancet Diabetes Endocrinol, 6, 714, 10.1016/S2213-8587(18)30137-2

Caleyachetty, 2017, Metabolically healthy obese and incident cardiovascular disease events among 3.5 Million men and women, J Am Coll Cardiol, 70, 1429, 10.1016/j.jacc.2017.07.763

Lassale, 2018, Separate and combined associations of obesity and metabolic health with coronary heart disease: a pan-European case-cohort analysis, Eur Heart J, 39, 397, 10.1093/eurheartj/ehx448

Ampuero, 2018, The effects of metabolic status on non-alcoholic fatty liver disease-related outcomes, beyond the presence of obesity, Aliment Pharmacol Ther, 48, 1260, 10.1111/apt.15015

Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study, Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038

Arrese, 2019, Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations, Expert Rev Gastroenterol Hepatol, 13, 849, 10.1080/17474124.2019.1649981

Chen, 2020, Lean NAFLD: a distinct entity shaped by differential metabolic adaptation, Hepatology, 71, 1213, 10.1002/hep.30908

Rastogi, 2017, Non-alcoholic fatty liver disease - histological scoring systems: a large cohort single-center, evaluation study, APMIS, 125, 962, 10.1111/apm.12742

Cho, 2019, Implications of the dynamic nature of metabolic health status and obesity on risk of incident cardiovascular events and mortality: a nationwide population-based cohort study, Metabolism, 97, 50, 10.1016/j.metabol.2019.05.002

Bril, 2017, Metabolic and histological implications of intrahepatic triglyceride content in nonalcoholic fatty liver disease, Hepatology, 65, 1132, 10.1002/hep.28985

Rotman, 2017, Liver fat accumulation as a barometer of insulin responsiveness again points to adipose tissue as the culprit, Hepatology, 65, 1088, 10.1002/hep.29094

McPherson, 2015, Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: Implications for prognosis and clinical management, J Hepatol, 62, 1148, 10.1016/j.jhep.2014.11.034

Pais, 2013, A systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver, J Hepatol, 59, 550, 10.1016/j.jhep.2013.04.027

Vilar-Gomez, 2018, Fibrosis severity as a determinant of cause-specific mortality in patients with Advanced nonalcoholic fatty liver disease: a multi-national cohort study, Gastroenterology, 155, 443, 10.1053/j.gastro.2018.04.034

Adams, 2005, The natural history of nonalcoholic fatty liver disease: a population-based cohort study, Gastroenterology, 129, 113, 10.1053/j.gastro.2005.04.014

Kleiner, 2019, Association of histologic disease activity with progression of nonalcoholic fatty liver disease, JAMA Netw Open, 2, e1912565, 10.1001/jamanetworkopen.2019.12565

Brunt, 2019, Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the nonalcoholic steatohepatitis clinical research network treatment trials, Hepatology, 70, 522, 10.1002/hep.30418

Ratziu V, Harrison SA, Francque S, Bedossa P, Anstee QM, Ben S, et al. ALT as a non-invasive biomarker of histological response to pharmacotherapy in NASH patients: insights from the elafibranor GOLDEN505 trial. 67th Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting 2016; 2016: Newcastle University.

Dufour, 2016, Time to abandon NASH?, Hepatology, 63, 9, 10.1002/hep.28276

Thuluvath, 2018, Is cryptogenic cirrhosis different from NASH cirrhosis?, J Hepatol, 68, 519, 10.1016/j.jhep.2017.11.018

Caldwell, 2018, Cryptogenic vs. NASH-cirrhosis: the rose exists well before its name…, J Hepatol, 68, 391, 10.1016/j.jhep.2017.12.006

Younossi, 2018, The conundrum of cryptogenic cirrhosis: adverse outcomes without treatment options, J Hepatol, 69, 1365, 10.1016/j.jhep.2018.08.013

Singal, 2018, ACG clinical guideline: alcoholic liver disease, Am J Gastroenterol, 113, 175, 10.1038/ajg.2017.469

Boyle, 2018, The bidirectional impacts of alcohol consumption and the metabolic syndrome: Cofactors for progressive fatty liver disease, J Hepatol, 68, 251, 10.1016/j.jhep.2017.11.006

Brunt, 2003, Concurrence of histologic features of steatohepatitis with other forms of chronic liver disease, Mod Pathol, 16, 49, 10.1097/01.MP.0000042420.21088.C7

Sanchez-Munoz, 2004, Histologic features of steatohepatitis in patients with a clinical diagnosis of autoimmune cholestasis, Dig Dis Sci, 49, 1957, 10.1007/s10620-004-9600-5

Cotrim, 1999, Nonalcoholic steatohepatitis: a toxic liver disease in industrial workers, Liver, 19, 299, 10.1111/j.1478-3231.1999.tb00053.x

De Luca-Johnson, 2016, Natural history of patients presenting with autoimmune hepatitis and coincident nonalcoholic fatty liver disease, Dig Dis Sci, 61, 2710, 10.1007/s10620-016-4213-3

Choi, 2020, Non-Alcoholic steatohepatitis is associated with liver-related outcomes and all-cause mortality in chronic hepatitis B, Hepatology, 71, 539, 10.1002/hep.30857

Chiang, 2014, The impact of obesity and metabolic syndrome on alcoholic liver disease, Clin Liver Dis, 18, 157, 10.1016/j.cld.2013.09.006

Ajmera, 2017, Is moderate alcohol use in nonalcoholic fatty liver disease good or bad? A critical review, Hepatology, 65, 2090, 10.1002/hep.29055

Ceballos, 2017, Editor's corner: binge drinking and the evolving language of alcohol research, J Stud Alcohol Drugs, 78, 488, 10.15288/jsad.2017.78.488

Cespiati, 2020, Genetics and epigenetics in the clinic: precision medicine in the management of fatty liver disease, Curr Pharm Des, 10.2174/1381612826666200122151251

Eslam, 2020, Genetic contributions to NAFLD: leveraging shared genetics to uncover systems biology, Nat Rev Gastroenterol Hepatol, 17, 40, 10.1038/s41575-019-0212-0

Eslam, 2018, Genetics and epigenetics of NAFLD and NASH: clinical impact, J Hepatol, 68, 268, 10.1016/j.jhep.2017.09.003

Fracanzani, 2017, Liver and cardiovascular damage in patients with lean nonalcoholic fatty liver disease, and association with visceral obesity, Clin Gastroenterol Hepatol, 15, 1604, 10.1016/j.cgh.2017.04.045

Hulley, 2007

Thông tin
Thông tin xuất bản

Journal of Hepatology

Tập 73 Số 1

202-209

Thông tin tác giả